CCL2 and Alzheimer disease: By inhibiting the MCP-1/CCR2 axis, it may be possible to decrease the infiltration of pro-inflammatory monocytes into the brain and simultaneously promote a reparative or Aβ-clearing macrophage phenotype (63, 64), these findings underscore the potential for translating MCP-1 modulation into tangible AD treatments.